Free tool
FAERS Monitor: Tyblume
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209405 or its brand name (Tyblume, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
596
Serious
432
72% of reports
Hospitalization
183
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea46
- headache39
- drug ineffective33
- fatigue31
- dizziness30
- vomiting30
- pulmonary embolism26
- anxiety24
- diarrhoea22
- off label use22
- dyspnoea21
- malaise21
- drug interaction20
- drug exposure during pregnancy19
- pain19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 21 |
| 2005 | 46 |
| 2006 | 19 |
| 2007 | 27 |
| 2008 | 16 |
| 2009 | 24 |
| 2010 | 27 |
| 2011 | 40 |
| 2012 | 36 |
| 2013 | 4 |
| 2014 | 10 |
| 2015 | 14 |
| 2016 | 21 |
| 2017 | 26 |
| 2018 | 20 |
| 2019 | 36 |
| 2020 | 35 |
| 2021 | 34 |
| 2022 | 22 |
| 2023 | 34 |
| 2024 | 33 |
| 2025 | 34 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,563 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug exposure during pregnancySignal | 19 | 19.7 | 12.7 | 320 |
| pulmonary embolismSignal | 26 | 9.7 | 6.6 | 194 |
| drug interactionSignal | 20 | 4.4 | 2.9 | 50 |
| anxietySignal | 24 | 3.0 | 2.0 | 30 |
| vomitingSignal | 30 | 2.3 | 1.6 | 20 |
| headacheSignal | 39 | 2.2 | 1.6 | 25 |
| dizzinessSignal | 30 | 2.1 | 1.5 | 17 |
| nauseaSignal | 46 | 2.1 | 1.6 | 25 |
| malaise | 21 | 1.7 | 1.1 | 5 |
| fatigue | 31 | 1.4 | 1.0 | 3 |
| dyspnoea | 21 | 1.3 | 0.9 | 1 |
| diarrhoea | 22 | 1.2 | 0.8 | 1 |
| pain | 19 | 1.1 | 0.7 | 0 |
| off label use | 22 | 0.9 | 0.6 | 0 |
| drug ineffective | 33 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.